“SOUL Trial: Oral Semaglutide and MACE Reduction Cardiovascular Protection from an Oral GLP-1 in High-Risk Type 2 Diabetes”. Diabzen, vol. 4, no. 19, July 2026, pp. 38-39, https://thediabzen.com/index.php/d/article/view/62.